Medullary thyroid cancer (MTC), a neuroendocrine tumor arising from the parafollicular C cells of the thyroid gland, is rare and accounts for approximately 5% of all thyroid cancers. The majority of cases of MTC are sporadic, and in roughly 25% of cases, MTC is part of a hereditary cancer syndrome with a well-characterized germline RET mutation: multiple endocrine neoplasia 2A, multiple endocrine neoplasia (MEN) 2B, or familial MTC.
The ZETA study was a randomized double-blind phase III trial in which patients were randomly assigned in a 2:1 fashion to receive oral vandetanib 300 mg per day (n ϭ 231) or a placebo (n ϭ 100) until disease progression. The primary end point was progression-free survival (PFS), and relevant secondary end points were objective response rate, overall survival, biochemical response, safety, and tolerability. Patients who were enrolled onto the ZETA trial were not required to have progressive disease before enrollment but were required to have measurable disease at baseline and a calcitonin level of at least 500 pg/mL. The study showed a significant prolongation of PFS with vandetanib versus the placebo (hazard ratio, 0.46; 95% CI, 0.31 to 0.69; P Ͻ .001). Statistically significant advantages for vandetanib were also seen for objective response rate, disease control rate, and biochemical response. This study allowed patients receiving the placebo to cross over to vandetanib, and an overall survival advantage was not seen at the time of the initial report. The median duration of treatment in the randomized phase was 90.1 weeks for vandetanib and 39.9 weeks for the placebo. The ZETA trial clearly included many patients with indolent disease, as evidenced by a PFS of 19.3 months in the placebo group (with an estimated PFS of 30 months in the vandetanib group). Adverse events such as diarrhea, rash, nausea, and hypertension occurred in more than 30% of patients receiving vandetanib. More patients required dose reduction of vandetanib compared with the placebo for adverse events or QTc prolongation (35% v 3%). Nineteen patients (8%) developed protocol-defined QTc prolongation, but there were no reports of torsades de pointes. The rate of treatment discontinuation because of toxicity was 12%.
Because of this risk of QT prolongation, vandetanib is currently only available through the US Food and Drug Administration Vandetanib Risk Evaluation Mitigation Strategy Program. This program is meant to educate practitioners about the risk, appropriate monitoring, and management of QT prolongation should it occur during vandetanib therapy.
The EXAM study 3 that is reported in the article that accompanies this editorial sought to examine the effect of cabozantinib in progressive MTC. Cabozantinib is a tyrosine kinase inhibitor (TKI) that targets three potentially important pathways in MTC: MET, vascular endothelial growth factor receptor 2, and RET.
EXAM is a double-blind phase III trial comparing oral cabozantinib at 140 mg per day with a placebo in 330 patients with documented radiographic progression of metastatic MTC. The primary end point is PFS. Other end points are response rate, overall survival, and safety. This study also used a 2:1 randomization schema, but unlike the ZETA trial, the EXAM study did not allow cross over to the active drug. The study met its primary end point of prolongation of PFS: 11.2 months for cabozantinib versus 4 months for the placebo (hazard ratio, 0.28; 95% CI, 0.19 to 0.4; P Ͻ .001). There is no survival advantage noted so far, and analysis is ongoing for the overall survival end point. Objective tumor response rates and biochemical responses were also significantly improved with cabozantinib.
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The toxicity of cabozantinib is significant; grade 3 or 4 adverse events were reported in 69% of patients. Most common grade 3 or 4 adverse events were diarrhea, hand-foot syndrome, and fatigue. Serious adverse events occurred in 42% of patients, and adverse events associated with vascular endothelial growth factor inhibition, such as hypertension, occurred more frequently with cabozantinib. Most importantly, 79% of patients had dose reductions and 16% of cabozantinib-treated patients discontinued treatment as a result of adverse events. Grade 5 lethal toxicity occurred in 16 patients (7%) who were treated with cabozantinib. Most of these toxicities were deemed to be related to the study drug (fistula, respiratory failure, sudden death, hemorrhage, sepsis, and cardiopulmonary failure). There were five (2%) such grade 5 events in patients who were treated with vandetanib on the ZETA trial.
There are differences between the ZETA and EXAM trials (Tables  1 and 2 ). The EXAM trial had a mandatory entry criterion of radiographic progressive disease in the previous 14 months. This was not an entry criterion in ZETA. However, the choice of 14 months is curious, given that this is not necessarily an accepted or well-studied criterion to define a patient population in need of therapy. It is also a measure that can still allow patients with indolent disease to be enrolled onto the trial. In the EXAM trial, patients with previous treatment with TKIs (21%) were allowed to participate in the study and showed a significant benefit from cabozantinib, whereas the ZETA trial did not report data on previous TKI therapy. Both agents produced objective responses (45% with vandetanib and 28% with cabozantinib).
The toxicity of cabozantinib at the dose studied, 140 mg per day, prompted a dose reduction in 79% of patients; thus, it would seem that this starting dose is not tolerable in many patients in this disease setting. This drug has shown an impressive activity in phase I testing that has resulted in an accelerated move into a phase III study without a large phase II program in thyroid cancer. 4 The EXAM study does serve as an important reminder of the significance of phase I and II testing in oncology so that an appropriate dose can be tested in phase III programs. It is also telling that cabozantinib dosing in other solid tumors is much lower than 140 mg per day and varies between 60 and 100 mg. A recent report on castrate-resistant prostate cancer used a dose of 100 mg per day, and dose reductions were implemented in 62% of patients. 5 Additional analysis of PFS in the EXAM study suggests that patients with lower and higher drug exposure may have equivalent PFS; therefore, it is quite possible that a lower dose may be as effective, with improved tolerability and less dose reduction and/or discontinuation. The US Food and Drug Administration has asked for a postmarketing clinical trial to evaluate the safety and efficacy of a lower cabozantinib dose. 6 Physicians treating patients with MTC now have two agents from which to choose. It is clear that both are active, with a significant prolongation of PFS. Calcitonin and CEA levels will often decrease dramatically with these agents, and that frequently gives the patient a sense of significant psychological relief. No overall survival benefit has been seen in these studies thus far, and the choice of agent must be individualized. There are no data to suggest that one agent is better, and the data presented to date do not support a notion of superiority or inferiority for one agent over the other. There are situations in which avoiding a drug that can prolong the QT interval is important, and in those cases, cabozantinib might be preferred. For example, patients who are already receiving drugs that prolong the QT interval or who have significant electrolyte imbalances might not be best suited for vandetanib, although the risk in such clinical settings needs additional study. What is quite clear is that both agents have significant adverse effects, and physicians should be familiar with their respective toxicity profiles so that toxicity can be identified early on and prompt dose reductions can be implemented. It is important to keep in mind that MTC is often an indolent disease, and many patients do not require immediate therapy. A great deal of clinical judgment still needs to be applied, and physicians should not rush to treat patients with these agents simply because they are available. Some parameters are helpful in making these treatment decisions. For example, a calcitonin doubling time of greater than 2 years is a strong predictor of indolent disease, and observation can safely be applied in those patients. 7 Conversely, symptomatic disease (with symptoms such as diarrhea and pain) can be regarded as a reason to initiate therapy.
Going forward, it is also important to continue to enroll patients onto clinical trials, given that we have still not achieved a demonstrable survival advantage with either drug. Quality-of-life measures should be closely examined in patients who are likely to take these drugs for an extended period of time (months and possibly years).
RET mutations seem to play a role as well. Both the EXAM and ZETA trials showed a significant benefit in PFS in patients with a RET 
